,11,12,13,14 Recently, the approval of anti-PD-1/PD-L1 immune checkpoint inhibition (ICI) antibodies for the treatment of advanced and metastatic MCC has improved patient outcomes for patients who are eligible for treatment.13 This evidence concerns the gene CD274 and Merkel cell skin cancer.